Received: 24 September 2021
Accepted: 15 November 2021
First Online: 8 December 2021
: The study was conducted in accordance with the institutional guidelines and approved by the Regional Committee of Medical and Health Research Ethics (REK) (Nor-COAST study, application number: REK no: 2017/2060. This sub-study, application number: REK no: 2015/171, Application ID: 12253). The study was registered at ExternalRef removed (NCT02650531). To participate, the patients had to be able to give written informed consent for themselves. Patients who were unable to express consent for themselves were also included if their next of kin did not decline. This is in line with the Norwegian consent procedures for patients not able to consent for themselves.
: Not applicable. The publication does not contain individual data.
: ABK has been/is the principal site investigator in three clinical trials (Boehringer-Ingelheim 1346.0023, Roche BN29553, and Novo Nordisk NN6535–4730), IS has been an investigator in the clinical trial Boehringer-Ingelheim 1346.0023 and part of the advisory board for Biogen.The rest of the authors do not have any competing interests to declare.